您当前所在的位置:首页 > 产品中心 > 产品信息
Methyldopa_分子结构_CAS_555-30-6)
点击图片或这里关闭

Methyldopa

产品号 DB00968 公司名称 DrugBank
CAS号 555-30-6 公司网站 http://www.ualberta.ca/
分子式 C10H13NO4 电 话 (780) 492-3111
分子量 211.21452 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 843

产品价格信息

请登录

产品别名

标题
Methyldopa
IUPAC标准名
(2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid
IUPAC传统名
methyldopa
商标名
Presolisin
Presinol
Aldomin
Novomedopa
Aldomet
Apo-Methyldopa
Baypresol
Becanta
Grospisk
Hyperpax
Medomet
Medopa
Medopal
Methoplain
Sedometil
Aldoclor-150
Aldoclor-250
Aldometil
Aldoril 15
Aldoril 25
Aldoril D30
Aldoril D50
Bayer 1440 L
Dopamet
Dopamethyperpax
Dopatec
Dopegyt
Hypolag
Medopren
Nu-Medopa
Sembrina
别名
L-Methyl Dopa
Alpha medopa
Mk. b51
Alphamethyldopa
AMD
Methyldopa anhydrous
Methyldopate
Methyldopate HCL

产品登记号

CAS号 555-30-6
PubChem SID 46508535
PubChem CID 38853

产品性质

疏水性(logP) -1.7
溶解度 1000 mg/L

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. [PubChem]
Indication For use in the treatment of hypertension.
Pharmacology Methyldopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Only methyldopa, the L-isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man the antihypertensive activity appears to be due solely to the L-isomer. About twice the dose of the racemate (DL-alpha-methyldopa) is required for equal antihypertensive effect. Methyldopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output usually is maintained without cardiac acceleration. In some patients the heart rate is slowed. Normal or elevated plasma renin activity may decrease in the course of methyldopa therapy. Methyldopa reduces both supine and standing blood pressure. Methyldopa usually produces highly effective lowering of the supine pressure with infrequent symptomatic postural hypotension. Exercise hypotension and diurnal blood pressure variations rarely occur.
Toxicity The oral LD50 of methyldopa is greater than 1.5 g/kg in both the mouse and the rat. Symptoms of overdose include bloating, constipation, diarrhea, dizziness, extreme drowsiness, gas, light-headedness, nausea, severely low blood pressure, slow heartbeat, vomiting, and weakness.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic, extensively metabolized. The known urinary metabolites are: a-methyldopa mono-0-sulfate; 3-0-methyl-a-methyldopa; 3,4-dihydroxyphenylacetone; a-methyldopamine; 3-0-methyl-a-methyldopamine and their conjugates.
Absorption Absorption from the gastrointestinal tract is variable but averages approximately 50%.
Half Life The plasma half-life of methyldopa is 105 minutes.
Protein Binding Low (less than 20%).
Elimination Methyldopa is extensively metabolized. The known urinary metabolites are: α-methyldopa mono-O-sulfate; 3-0-methyl-α-methyldopa; 3,4-dihydroxyphenylacetone; α-methyldopamine; 3-0-methyl-α-methyldopamine and their conjugates. Approximately 70 percent of the drug which is absorbed is excreted in the urine as methyldopa and its mono-O-sulfate conjugate. Methyldopa crosses the placental barrier, appears in cord blood, and appears in breast milk.
Clearance * Renal cl=130 mL/min [healthy]
References
Mah GT, Tejani AM, Musini VM: Methyldopa for primary hypertension. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD003893. [Pubmed]
McCoy S, Baldwin K: Pharmacotherapeutic options for the treatment of preeclampsia. Am J Health Syst Pharm. 2009 Feb 15;66(4):337-44. [Pubmed]
Sica DA: Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007 May;9(5):399-405. [Pubmed]
van Zwieten PA: Development and trends in the drug treatment of essential hypertension. J Hypertens Suppl. 1992 Dec;10(7):S1-12. [Pubmed]
Rosenthal T, Oparil S: The effect of antihypertensive drugs on the fetus. J Hum Hypertens. 2002 May;16(5):293-8. [Pubmed]
van Zwieten PA, Timmermans PB: Pharmacology and characterization of central alpha-adrenoceptors involved in the effect of centrally acting antihypertensive drugs. Chest. 1983 Feb;83(2 Suppl):340-3. [Pubmed]
van Zwieten PA: Pharmacology of centrally acting hypotensive drugs. Br J Clin Pharmacol. 1980;10 Suppl 1:13S-20S. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献

  • Mah GT, Tejani AM, Musini VM: Methyldopa for primary hypertension. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD003893. Pubmed
  • McCoy S, Baldwin K: Pharmacotherapeutic options for the treatment of preeclampsia. Am J Health Syst Pharm. 2009 Feb 15;66(4):337-44. Pubmed
  • Sica DA: Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007 May;9(5):399-405. Pubmed
  • van Zwieten PA: Development and trends in the drug treatment of essential hypertension. J Hypertens Suppl. 1992 Dec;10(7):S1-12. Pubmed
  • Rosenthal T, Oparil S: The effect of antihypertensive drugs on the fetus. J Hum Hypertens. 2002 May;16(5):293-8. Pubmed
  • van Zwieten PA, Timmermans PB: Pharmacology and characterization of central alpha-adrenoceptors involved in the effect of centrally acting antihypertensive drugs. Chest. 1983 Feb;83(2 Suppl):340-3. Pubmed
  • van Zwieten PA: Pharmacology of centrally acting hypotensive drugs. Br J Clin Pharmacol. 1980;10 Suppl 1:13S-20S. Pubmed